What is Lifecore Biomedical, Inc.'s earnings per share (EPS)?

Lifecore Biomedical, Inc. (LFCR) reported diluted earnings per share of -$1.27 for fiscal year 2025. This represents a -484.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lifecore Biomedical, Inc. (LFCR) Financials

LFCR

FY2025 annual

Revenue $128.9M +0.5% YoY

Net Income -$38.7M -422.5% YoY

EPS (Diluted) -$1.27 -484.8% YoY

Free Cash Flow -$13.6M +24.9% YoY

Market Cap $243.4M as of Oct 13, 2026

Price / Sales 1.9x on $128.9M revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book n/m negative shareholder equity, so no book multiple, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE May

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LFCR SEC filings page.

Lifecore Biomedical, Inc. (LFCR) reported $128.9M in revenue for fiscal year 2025, up 0.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LFCR FY2025 2026-10-04

Revenue has plateaued near $129M, while operating losses and interest costs have pushed the balance sheet into negative equity.

FY2024’s accounting profit of $12M produced only $257K of operating cash flow. The next year’s net loss of $38.7M coincided with negative operating cash flow, while capital spending still left free cash flow at -$13.6M, showing earnings have not consistently translated into cash.

Gross margin slipped from 32.6% to 31.3%, showing weaker gross economics rather than a scale benefit. Operating margin then widened from -6.9% to -13.4%, indicating overhead absorbed more gross profit despite little top-line expansion.

By FY2025, liabilities slightly exceeded assets, leaving equity at -$861K. A 2.8x current ratio indicates near-term current assets exceeded current obligations, but it does not offset broader solvency strain alongside $130.4M of long-term debt.

Financial Health Signals

Financial Health Score 52/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Lifecore Biomedical, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Lifecore Biomedical, Inc. held $8.3M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $206K of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Lifecore Biomedical, Inc. scores 99/100 among other emerging companies.

Dilution

Lifecore Biomedical, Inc. had 37M shares outstanding at the end of fiscal year 2025, against 31M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Lifecore Biomedical, Inc. scores 35/100 among other emerging companies.

R&D Intensity

Lifecore Biomedical, Inc. spent $8.3M on research and development in fiscal year 2025, which was 5.7% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Lifecore Biomedical, Inc. scores 26/100 among other emerging companies.

Revenue Progress

Lifecore Biomedical, Inc. reported revenue of $128.9M in fiscal year 2025, against $128.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Lifecore Biomedical, Inc. scores 57/100 among other emerging companies.

Burn Trend

Lifecore Biomedical, Inc.'s operations used $206K of cash in fiscal year 2025, against $257K generated in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Lifecore Biomedical, Inc. scores 87/100 among other emerging companies.

Balance Sheet

Lifecore Biomedical, Inc.'s cash, cash equivalents and investments came to $8.3M at the end of fiscal year 2025, against $240.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Lifecore Biomedical, Inc. scores 7/100 among other emerging companies.

Altman Z-Score Distress

-0.01

Lifecore Biomedical, Inc. scores -0.01, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($243.4M) relative to total liabilities ($240.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak

3/9

Lifecore Biomedical, Inc. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Lifecore Biomedical, Inc. reported a net loss of $38.7M while operations used $206K of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Lifecore Biomedical, Inc. reported an operating loss of $17.2M against $22.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$34.2M

QoQ+47.3%

Lifecore Biomedical, Inc. generated $34.2M in revenue in Q1 2027. Against the prior quarter it is up 47.3%.

EBITDA

$5.1M

QoQ+320.5%

Lifecore Biomedical, Inc.'s EBITDA was $5.1M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. Against the prior quarter it is up 320.5%.

Net Income

-$6.2M

QoQ+58.9%

Lifecore Biomedical, Inc. reported -$6.2M in net income in Q1 2027. Against the prior quarter it is up 58.9%.

EPS (Diluted)

-$0.19

QoQ+55.8%

Lifecore Biomedical, Inc. earned -$0.19 per diluted share (EPS) in Q1 2027. Against the prior quarter it is up 55.8%.

Cash & Balance Sheet

Free Cash Flow

-$2.7M

QoQ-175.4%

Lifecore Biomedical, Inc. recorded an outflow of $2.7M in free cash flow in Q1 2027, representing a cash shortfall after capex. Against the prior quarter it is down 175.4%.

Cash & Debt

$17.2M

QoQ-17.1%

5Y CAGR+86.6%

10Y CAGR+5.6%

Lifecore Biomedical, Inc. held $17.2M in cash against $155.1M in long-term debt as of Q1 2027.

Shares Outstanding

38M

QoQ+0.9%

Lifecore Biomedical, Inc. had 38M shares outstanding in Q1 2027. Against the prior quarter it is up 0.9%.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Gross Margin

35.3%

QoQ+16.1pp

Lifecore Biomedical, Inc.'s gross margin was 35.3% in Q1 2027, indicating the percentage of revenue retained after direct costs. Against the prior quarter it is up 16.1 percentage points.

Operating Margin

7.5%

QoQ+27.6pp

Lifecore Biomedical, Inc.'s operating margin was 7.5% in Q1 2027, reflecting core business profitability. Against the prior quarter it is up 27.6 percentage points.

Net Margin

-18.0%

QoQ+46.6pp

Lifecore Biomedical, Inc.'s net profit margin was -18.0% in Q1 2027, showing the share of revenue converted to profit. Against the prior quarter it is up 46.6 percentage points.

Return on Equity

Not reported for Q1 2027.

Capital Allocation

R&D Spending

$1.5M

QoQ+26.3%

Lifecore Biomedical, Inc. invested $1.5M in research and development in Q1 2027. Against the prior quarter it is up 26.3%.

Capital Expenditures

$513K

QoQ-54.1%

Lifecore Biomedical, Inc. invested $513K in capex in Q1 2027, funding long-term assets and infrastructure. Against the prior quarter it is down 54.1%.

Share Buybacks

Not reported for Q1 2027.

LFCR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LFCR quarterly income statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$128.9M+0.5%	$128.3M+24.2%	$103.3M-7.2%	$111.3M+10.3%	$100.9M-37.0%	$160.1M-71.3%	$557.6M+6.4%	$524.2M+11.6%	$469.8M-1.5%	$476.9M-11.6%	$539.3M+13.1%	$476.8M+7.9%	$441.7M+39.1%	$317.6M+14.8%	$276.7M
Cost of Revenue	$88.6M+2.5%	$86.4M+14.8%	$75.3M+4.3%	$72.2M+16.6%	$61.9M-48.7%	$120.7M-74.7%	$476.6M+6.9%	$445.9M+14.2%	$390.6M-4.8%	$410.1M-13.4%	$473.9M+14.4%	$414.2M+9.3%	$378.9M+42.8%	$265.4M+15.4%	$230.0M
Gross Profit	$40.3M-3.7%	$41.9M+49.5%	$28.0M-28.4%	$39.1M+0.3%	$38.9M-1.1%	$39.4M-51.4%	$81.0M+3.4%	$78.3M-1.1%	$79.2M+18.6%	$66.8M+2.1%	$65.4M+4.5%	$62.6M-0.3%	$62.8M+20.4%	$52.1M+11.7%	$46.7M
R&D Expenses	$8.3M-3.7%	$8.6M-1.8%	$8.7M+11.4%	$7.8M+17.3%	$6.7M-11.8%	$7.6M-33.9%	$11.5M-10.4%	$12.8M+35.1%	$9.5M+31.1%	$7.2M+3.4%	$7.0M-3.0%	$7.2M-22.5%	$9.3M-3.4%	$9.6M+3.8%	$9.3M
SG&A Expenses	$44.0M+8.9%	$40.5M+3.8%	$39.0M+12.4%	$34.7M+25.0%	$27.7M-31.8%	$40.7M-34.5%	$62.1M+19.5%	$52.0M-1.0%	$52.5M+13.7%	$46.2M+15.6%	$40.0M+13.6%	$35.2M+8.1%	$32.5M+22.7%	$26.5M+7.7%	$24.6M
Operating Income	-$17.2M-95.0%	-$8.8M+59.4%	-$21.8M-84.9%	-$11.8M-33.6%	-$8.8M+65.9%	-$25.9M-572.6%	$5.5M-59.7%	$13.6M-7.4%	$14.7M+171.1%	-$20.6M-211.7%	$18.5M-8.6%	$20.2M-18.8%	$24.9M+70.6%	$14.6M+81.5%	$8.0M
EBITDA	-$9.2M-935.7%	-$890K+89.7%	-$8.6M-237.5%	$6.3M-43.2%	$11.0M+256.9%	-$7.0M-134.0%	$20.7M-20.4%	$26.0M+2.6%	$25.3M+325.6%	-$11.2M-144.0%	$25.6M-6.4%	$27.3M-15.1%	$32.2M+59.2%	$20.2M+51.4%	$13.3M
Interest Expense	$22.2M+22.2%	$18.1M+2.8%	$17.6M+13.5%	$15.6M+74.1%	$8.9M+92.3%	$4.6M	N/A	N/A	N/A	$2.0M+8.6%	$1.8M+10.8%	$1.6M-17.8%	$2.0M+116.1%	$929K+13.3%	$820K
Income Tax	$43K-76.5%	$183K-40.6%	$308K+105.9%	-$5.2M+17.9%	-$6.3M+27.6%	-$8.8M-678.0%	$1.5M+116.2%	-$9.4M-331.8%	$4.0M+152.4%	-$7.7M-199.5%	$7.7M-26.8%	$10.6M+12.0%	$9.5M+31.6%	$7.2M+71.8%	$4.2M
Net Income	-$38.7M-422.5%	$12.0M+112.0%	-$99.6M+14.7%	-$116.7M-261.4%	-$32.3M+15.4%	-$38.2M-9392.2%	$411K-98.3%	$24.8M+134.5%	$10.6M+191.0%	-$11.6M-185.9%	$13.5M-29.3%	$19.1M-15.2%	$22.6M+77.9%	$12.7M+223.9%	$3.9M
EPS (Basic)	-$1.27-425.6%	$0.39+111.7%	-$3.32+16.4%	-$3.97-260.9%	-$1.10+16.0%	-$1.31-13200.0%	$0.01-98.9%	$0.90+130.8%	$0.39+190.7%	-$0.43-186.0%	$0.50-30.6%	$0.72-17.2%	$0.87+77.6%	$0.49+226.7%	$0.15
EPS (Diluted)	-$1.27-484.8%	$0.33+109.9%	-$3.32+16.4%	-$3.97-260.9%	-$1.10+16.0%	-$1.31-13200.0%	$0.01-98.9%	$0.89+134.2%	$0.38+188.4%	-$0.43-186.0%	$0.50-29.6%	$0.71-16.5%	$0.85+73.5%	$0.49+226.7%	$0.15
Diluted Shares (Avg)	35M-5.0%	37M+22.4%	30M+1.7%	29M+0.6%	29M+0.5%	29M+1.9%	29M+2.5%	28M+1.0%	28M+2.2%	27M-1.1%	27M+0.8%	27M+101755.3%	26,626-99.9%	26M-1.9%	27M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Revenue	$34.2M	$23.2M-36.4%	N/A	$31.1M-4.5%	$36.4M-3.8%	$35.2M-1.5%	$32.6M+8.0%	$24.7M+0.7%
Cost of Revenue	$22.1M	$18.7M-16.6%	N/A	$23.3M+8.6%	$22.5M+9.0%	$25.3M+6.3%	$21.5M+6.4%	$19.3M-11.4%
Gross Profit	$12.1M	$4.5M-68.1%	N/A	$7.8M-29.7%	$14.0M-19.0%	$9.8M-17.2%	$11.1M+11.3%	$5.4M+97.5%
R&D Expenses	$1.5M	$1.2M-42.1%	N/A	$2.0M+2.0%	$2.1M-2.7%	$2.0M-5.8%	$1.9M-8.3%	$2.2M+1.9%
SG&A Expenses	$8.0M	$7.9M-11.8%	N/A	$8.9M-20.0%	$9.0M-25.6%	$10.0M+1.3%	$11.1M+19.0%	$14.8M+60.8%
Operating Income	$2.6M	-$4.7M-187.7%	N/A	-$3.1M-56.6%	$5.3M+148.0%	-$9.0M-908.8%	-$2.0M-32.1%	-$11.6M-34.5%
EBITDA	$5.1M	-$2.3M-131.9%	N/A	-$1.1M-1377.6%	$7.3M+84.7%	-$7.0M-725.8%	$85K-83.1%	-$9.6M-48.8%
Interest Expense	$7.8M	$7.3M+28.3%	N/A	$6.4M	$5.7M	$5.6M+30.3%	N/A	$5.4M
Income Tax	$23K	$43K+30.3%	N/A	$333K+674.4%	$33K+157.9%	-$8K-103.7%	$43K+166.2%	-$25K-128.4%
Net Income	-$6.2M	-$15.0M-1206.0%	N/A	-$10.0M-52.0%	-$1.1M+83.8%	-$14.8M-194.5%	-$6.6M-146.2%	-$16.2M-50.9%
EPS (Basic)	-$0.19	-$0.43-616.7%	N/A	-$0.29-16.0%	-$0.06+73.9%	-$0.42-182.4%	-$0.25-153.2%	-$0.53-51.4%
EPS (Diluted)	-$0.19	-$0.43	N/A	-$0.29-16.0%	-$0.06	-$0.42-200.0%	-$0.25-164.1%	-$0.53-51.4%
Diluted Shares (Avg)	38M	37M	N/A	37M+8.9%	37M	37M+1.1%	34M-5.7%	31M+1.5%

LFCR Balance Sheet

LFCR quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$239.3M-5.8%	$254.0M+0.2%	$253.5M-7.7%	$274.7M-45.3%	$501.9M+71.0%	$293.5M-43.5%	$519.1M+28.3%	$404.7M+12.9%	$358.6M+4.7%	$342.7M-1.1%	$346.5M+10.5%	$313.6M+7.8%	$290.9M+4.8%	$277.7M+34.6%	$206.3M
Current Assets	$85.7M+5.7%	$81.0M-13.7%	$93.9M-19.5%	$116.7M-19.7%	$145.3M-7.5%	$157.1M+18.1%	$133.0M+37.1%	$97.1M+19.4%	$81.3M-5.8%	$86.3M-7.4%	$93.2M+2.5%	$90.9M+6.2%	$85.7M+5.5%	$81.2M-5.2%	$85.6M
Cash & Equivalents	$8.3M-2.3%	$8.5M-55.7%	$19.1M+1826.4%	$991K+29.9%	$763K+111.9%	$360K-66.7%	$1.1M-62.7%	$2.9M-51.7%	$6.0M-39.8%	$10.0M-29.4%	$14.1M-0.8%	$14.2M+3.8%	$13.7M-38.1%	$22.2M+172.6%	$8.1M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$1.5M	$0-100.0%	$28.1M
Inventory	$32.3M-19.2%	$40.0M-2.1%	$40.8M+13.4%	$36.0M+6.1%	$33.9M-48.8%	$66.3M+22.5%	$54.1M+70.1%	$31.8M+34.7%	$23.6M-7.5%	$25.5M+2.0%	$25.0M+1.2%	$24.7M+2.6%	$24.1M+9.5%	$22.0M+9.2%	$20.2M
Accounts Receivable	N/A	$31.2M+7.3%	$29.0M-24.2%	$38.3M+21.3%	$31.6M-58.5%	$76.2M+9.5%	$69.6M+29.1%	$53.9M+17.4%	$45.9M-1.1%	$46.4M-0.2%	$46.5M+4.6%	$44.4M+21.9%	$36.4M+14.0%	$32.0M+47.6%	$21.7M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M-59.1%	$33.9M-55.8%	$76.7M+40.8%	$54.5M0.0%	$54.5M+9.9%	$49.6M0.0%	$49.6M0.0%	$49.6M0.0%	$49.6M0.0%	$49.6M+36.1%	$36.5M
Total Liabilities	$240.2M+20.1%	$200.1M-8.4%	$218.5M+16.9%	$186.9M-37.7%	$299.9M+371.1%	$63.7M-74.4%	$248.9M+63.6%	$152.1M+16.6%	$130.5M+0.1%	$130.3M+3.1%	$126.4M+16.1%	$108.9M-1.5%	$110.5M-12.4%	$126.1M+83.9%	$68.6M
Current Liabilities	$30.2M-22.4%	$38.9M-1.1%	$39.3M-77.8%	$176.6M+73.4%	$101.9M	N/A	$137.1M+55.1%	$88.4M+71.8%	$51.5M-8.7%	$56.3M+0.3%	$56.2M+16.1%	$48.4M-4.7%	$50.8M-23.9%	$66.7M+117.2%	$30.7M
Non-Current Liabilities	$210.0M+30.3%	$161.2M-10.0%	$179.2M+1639.7%	$10.3M-94.8%	$198.1M	N/A	$111.9M+75.4%	$63.8M-19.3%	$79.0M+6.8%	$74.0M+5.4%	$70.2M+16.1%	$60.5M+1.2%	$59.8M+0.5%	$59.5M+56.9%	$37.9M
Long-Term Debt	$130.4M+29.4%	$100.8M+19.7%	$84.3M	N/A	$164.9M	N/A	$87.2M+133.4%	$37.4M-11.7%	$42.3M-8.0%	$46.0M+34.6%	$34.2M+20.7%	$28.3M-17.6%	$34.4M-14.7%	$40.3M+160.0%	$15.5M
Total Equity	-$861K-107.6%	$11.3M+367.5%	-$4.2M-104.8%	$87.8M-56.5%	$201.9M-12.1%	$229.8M-14.9%	$270.1M+7.0%	$252.6M+11.5%	$226.6M+7.5%	$210.7M-3.5%	$218.4M+7.6%	$203.1M+13.6%	$178.7M+19.3%	$149.7M+10.1%	$136.1M
Retained Earnings	-$205.2M-23.3%	-$166.5M+6.7%	-$178.5M-126.1%	-$79.0M-309.2%	$37.7M-47.0%	$71.2M-35.1%	$109.7M+0.4%	$109.3M+29.4%	$84.5M+15.0%	$73.5M-13.7%	$85.1M+18.9%	$71.6M+36.5%	$52.4M+75.7%	$29.8M+74.1%	$17.1M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Total Assets	$229.5M	$225.5M-5.8%	$232.2M-2.3%	$235.2M-7.9%	$239.3M-5.8%	$237.7M-3.5%	$255.4M+3.9%	$246.8M+0.5%
Current Assets	$83.7M	$77.6M-9.4%	$82.3M-2.3%	$83.9M+2.5%	$85.7M+5.7%	$84.2M+10.6%	$81.9M+6.7%	$74.2M-10.4%
Cash & Equivalents	$17.2M	$20.8M+151.6%	$17.5M+222.5%	$18.9M+99.4%	$8.3M-2.3%	$5.4M+76.3%	$9.5M+193.5%	$5.5M-36.1%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$25.5M	$28.2M-12.8%	$29.1M-15.9%	$33.8M-13.8%	$32.3M-19.2%	$34.6M-12.8%	$39.2M-5.4%	$41.6M-0.1%
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$30.3M	$25.1M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$13.9M	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%
Total Liabilities	$263.6M	$253.9M+5.7%	$246.4M+29.5%	$245.7M+25.6%	$240.2M+20.1%	$190.3M+1.9%	$195.6M-3.9%	$207.3M-5.4%
Current Liabilities	$21.6M	$20.5M-32.1%	$23.6M-24.2%	$30.0M-15.1%	$30.2M-22.4%	$31.1M-15.5%	$35.3M-12.3%	$40.5M+14.4%
Non-Current Liabilities	$242.0M	$233.4M+11.1%	$222.8M+40.0%	$215.8M+34.6%	$210.0M+30.3%	$159.2M+6.1%	$160.3M-1.8%	$166.8M-9.2%
Long-Term Debt	$155.1M	$148.7M+14.0%	$142.2M+13.8%	$136.0M+23.0%	$130.4M+29.4%	$124.9M+29.7%	$110.5M+20.0%	$105.5M+19.9%
Total Equity	-$34.1M	-$28.4M-3202.9%	-$14.2M-739.4%	-$10.5M-168.2%	-$861K-107.6%	$2.2M-87.4%	$15.4M+987.2%	-$3.9M+71.0%
Retained Earnings	-$244.3M	-$238.2M-16.0%	-$223.2M-9.4%	-$218.1M-13.9%	-$205.2M-23.3%	-$204.1M-28.0%	-$191.5M-9.4%	-$182.8M+3.5%

LFCR Cash Flow Statement

LFCR quarterly cash flow statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$206K-180.2%	$257K+101.5%	-$17.4M+22.8%	-$22.6M-237.2%	$16.5M+196.7%	-$17.0M-206.4%	$16.0M-19.0%	$19.8M-33.7%	$29.8M+43.7%	$20.8M-22.0%	$26.6M+26.5%	$21.0M-0.9%	$21.2M-4.3%	$22.2M+53.3%	$14.5M
Depreciation & Amortization	$8.0M+0.9%	$8.0M-39.6%	$13.2M-27.0%	$18.1M-9.1%	$19.9M+5.5%	$18.8M+23.7%	$15.2M+22.7%	$12.4M+16.2%	$10.7M+13.6%	$9.4M+32.5%	$7.1M-0.3%	$7.1M-2.5%	$7.3M+29.8%	$5.6M+5.8%	$5.3M
Stock-Based Compensation	$10.2M+63.8%	$6.2M+71.7%	$3.6M+38.5%	$2.6M-22.4%	$3.4M+38.9%	$2.4M-32.1%	$3.6M-19.1%	$4.4M+11.1%	$4.0M+14.4%	$3.5M+119.7%	$1.6M+16.3%	$1.4M-20.0%	$1.7M-9.5%	$1.9M-4.0%	$2.0M
Capital Expenditures	$13.4M-27.1%	$18.4M	N/A	$26.2M+36.1%	$19.3M+57.7%	$12.2M-72.7%	$44.7M+33.2%	$33.6M+46.0%	$23.0M-42.1%	$39.7M+126.7%	$17.5M+17.6%	$14.9M+67.7%	$8.9M+65.3%	$5.4M-19.6%	$6.7M
Free Cash Flow	-$13.6M+24.9%	-$18.1M	N/A	-$48.8M-1647.9%	-$2.8M+90.5%	-$29.3M-1.9%	-$28.7M-107.9%	-$13.8M-302.1%	$6.8M+136.1%	-$18.9M-307.9%	$9.1M+47.9%	$6.2M-50.1%	$12.4M-26.5%	$16.8M+115.9%	$7.8M
Investing Cash Flow	-$6.4M+65.1%	-$18.4M-282.4%	-$4.8M-106.0%	$80.0M+749.6%	-$12.3M+48.5%	-$23.9M+75.3%	-$96.8M-172.0%	-$35.6M-40.0%	-$25.4M+37.1%	-$40.4M	N/A	N/A	-$10.4M+76.4%	-$44.1M-50.0%	-$29.4M
Financing Cash Flow	$6.4M-14.4%	$7.5M-81.1%	$39.7M+169.6%	-$57.0M-1567.8%	-$3.4M-108.5%	$40.0M-49.4%	$79.0M+494.5%	$13.3M+251.0%	-$8.8M-157.1%	$15.4M	N/A	N/A	-$19.3M-153.6%	$35.9M+854.3%	-$4.8M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$5.0M+322.8%	$1.2M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Operating Cash Flow	-$2.2M	$4.7M-12.1%	N/A	$1.8M+128.7%	$5.3M-38.7%	$1.2M+184.6%	-$6.1M-576.7%	-$613K+92.6%
Depreciation & Amortization	$2.6M	$2.4M+20.3%	N/A	$2.0M-3.1%	$2.0M-3.0%	$2.1M+3.5%	$2.0M+2.9%	$2.0M-8.1%
Stock-Based Compensation	$2.1M	$1.7M-6.4%	N/A	$2.4M-29.1%	$1.8M	$2.6M+70.8%	$3.4M+113.8%	$2.4M+57.8%
Capital Expenditures	$513K	$1.1M-46.7%	N/A	$1.7M-28.8%	$2.1M-22.7%	$5.5M-14.3%	$2.4M-42.7%	$3.4M-32.3%
Free Cash Flow	-$2.7M	$3.6M+10.2%	N/A	$25K+100.3%	$3.3M-45.9%	-$4.3M+45.3%	-$8.6M-188.6%	-$4.0M+69.8%
Investing Cash Flow	-$513K	-$1.1M+46.7%	N/A	-$1.7M+28.8%	-$2.1M+22.7%	$1.5M+124.3%	-$2.4M+42.7%	-$3.4M+32.3%
Financing Cash Flow	-$852K	-$256K+36.3%	N/A	-$1.4M-111.1%	-$402K+34.5%	-$6.8M-188.8%	$12.5M+611.2%	$1.1M-62.7%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

LFCR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LFCR quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	31.3%-1.4pp	32.6%+5.5pp	27.1%-8.0pp	35.1%-3.5pp	38.6%+14.0pp	24.6%+10.1pp	14.5%-0.4pp	14.9%-1.9pp	16.9%+2.9pp	14.0%+1.9pp	12.1%-1.0pp	13.1%-1.1pp	14.2%-2.2pp	16.4%-0.4pp	16.9%
Operating Margin	-13.4%-6.5pp	-6.9%+14.2pp	-21.1%-10.5pp	-10.6%-1.9pp	-8.8%+7.4pp	-16.2%-17.2pp	1.0%-1.6pp	2.6%-0.5pp	3.1%+7.4pp	-4.3%-7.8pp	3.4%-0.8pp	4.2%-1.4pp	5.6%+1.0pp	4.6%+1.7pp	2.9%
Net Margin	-30.0%-39.4pp	9.4%+105.8pp	-96.5%	-104.9%	-32.0%-8.1pp	-23.9%-23.9pp	0.1%-4.7pp	4.7%+2.5pp	2.3%+4.7pp	-2.4%-5.0pp	2.5%-1.5pp	4.0%-1.1pp	5.1%+1.1pp	4.0%+2.6pp	1.4%
Return on Equity	N/A	106.0%	N/A	-132.9%-116.9pp	-16.0%+0.6pp	-16.6%-16.8pp	0.1%-9.7pp	9.8%+5.2pp	4.7%+10.2pp	-5.5%-11.7pp	6.2%-3.2pp	9.4%-3.2pp	12.6%+4.2pp	8.5%+5.6pp	2.9%
Return on Assets	-16.2%-20.9pp	4.7%+44.0pp	-39.3%+3.2pp	-42.5%-36.1pp	-6.4%+6.6pp	-13.0%-13.1pp	0.1%-6.1pp	6.1%+3.2pp	2.9%+6.3pp	-3.4%-7.3pp	3.9%-2.2pp	6.1%-1.7pp	7.8%+3.2pp	4.6%+2.7pp	1.9%
Current Ratio	2.84+0.8x	2.08-0.3x	2.39+1.7x	0.66-0.8x	1.43	N/A	0.97-0.1x	1.10-0.5x	1.580.0x	1.53-0.1x	1.66-0.2x	1.88+0.2x	1.69+0.5x	1.22-1.6x	2.79
Debt-to-Equity	N/A	8.91	N/A	2.13+1.3x	0.82+0.5x	0.280.0x	0.32+0.2x	0.150.0x	0.190.0x	0.22+0.1x	0.160.0x	0.14-0.1x	0.19-0.1x	0.27+0.2x	0.11
Asset Turnover	0.540.0x	0.51+0.1x	0.410.0x	0.41+0.2x	0.20-0.3x	0.55-0.5x	1.07-0.2x	1.300.0x	1.31-0.1x	1.39-0.2x	1.560.0x	1.520.0x	1.52+0.4x	1.14-0.2x	1.34
FCF Margin	-10.6%+3.6pp	-14.1%	N/A	-43.9%-41.1pp	-2.8%+15.5pp	-18.3%-13.1pp	-5.1%-2.5pp	-2.6%-4.1pp	1.5%+5.4pp	-4.0%-5.7pp	1.7%+0.4pp	1.3%-1.5pp	2.8%-2.5pp	5.3%+2.5pp	2.8%

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Gross Margin	35.3%	19.2%-19.1pp	N/A	25.0%-9.0pp	38.4%-7.2pp	28.0%-5.3pp	34.0%+1.0pp	21.8%+10.7pp
Operating Margin	7.5%	-20.1%-34.8pp	N/A	-9.9%-3.8pp	14.6%+8.9pp	-25.7%-23.2pp	-6.0%-1.1pp	-46.9%-11.8pp
Net Margin	-18.0%	-64.6%-61.4pp	N/A	-32.1%-11.9pp	-3.1%+15.6pp	-42.0%-85.8pp	-20.2%-67.3pp	-65.7%-21.9pp
Return on Equity	N/A	N/A	N/A	N/A	N/A	-665.0%-753.4pp	-42.5%-1043.1pp	N/A
Return on Assets	-2.7%	-6.6%-6.2pp	N/A	-4.3%-1.7pp	-0.5%+2.3pp	-6.2%-12.6pp	-2.6%-8.3pp	-6.6%-2.2pp
Current Ratio	3.87	3.79+0.9x	3.49+0.8x	2.80+0.5x	2.84+0.8x	2.71+0.6x	2.32+0.4x	1.83-0.5x
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	56.25+50.8x	7.15-57.6x	N/A
Asset Turnover	0.15	0.100.0x	N/A	0.130.0x	0.150.0x	0.150.0x	0.130.0x	0.100.0x
FCF Margin	-7.9%	15.4%+6.5pp	N/A	0.1%+26.4pp	8.9%-6.9pp	-12.1%+9.7pp	-26.4%-16.5pp	-16.3%+38.2pp

Note: Shareholder equity is negative (-$861K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Lifecore Biomedical, Inc. LFCR	FY2025	$128.9M	-$38.7M	-30.0%	$243.4M	52/100
Alpha Teknova, Inc. TKNO	FY2025	$40.5M	-$17.3M	-42.6%	$467.1M	48/100
China SXT Pharmaceuticals, Inc. SXTC	FY2026	$1.1M	-$6.2M	N/A	$135K	33/100
Ironwood Pharmaceuticals, Inc. IRWD	FY2025	$296.2M	$24.0M	8.1%	$621.3M	34/100

Where Lifecore Biomedical, Inc. Ranks

Frequently Asked Questions

What is Lifecore Biomedical, Inc.'s annual revenue?

Lifecore Biomedical, Inc. (LFCR) reported $128.9M in total revenue for fiscal year 2025. This represents a 0.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Lifecore Biomedical, Inc.'s revenue growing?

Lifecore Biomedical, Inc. (LFCR) revenue grew by 0.5% year-over-year, from $128.3M to $128.9M in fiscal year 2025.

Is Lifecore Biomedical, Inc. profitable?

No, Lifecore Biomedical, Inc. (LFCR) reported a net income of -$38.7M in fiscal year 2025, with a net profit margin of -30.0%.

What is Lifecore Biomedical, Inc.'s EBITDA?

Lifecore Biomedical, Inc. (LFCR) had EBITDA of -$9.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Lifecore Biomedical, Inc. have?

As of fiscal year 2025, Lifecore Biomedical, Inc. (LFCR) had $8.3M in cash and equivalents against $130.4M in long-term debt.

What is Lifecore Biomedical, Inc.'s gross margin?

Lifecore Biomedical, Inc. (LFCR) had a gross margin of 31.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Lifecore Biomedical, Inc.'s operating margin?

Lifecore Biomedical, Inc. (LFCR) had an operating margin of -13.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Lifecore Biomedical, Inc.'s net profit margin?

Lifecore Biomedical, Inc. (LFCR) had a net profit margin of -30.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Lifecore Biomedical, Inc.'s free cash flow?

Lifecore Biomedical, Inc. (LFCR) recorded an outflow of $13.6M in free cash flow during fiscal year 2025. This represents a 24.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Lifecore Biomedical, Inc.'s operating cash flow?

Lifecore Biomedical, Inc. (LFCR) recorded an outflow of $206K in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Lifecore Biomedical, Inc.'s total assets?

Lifecore Biomedical, Inc. (LFCR) had $239.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Lifecore Biomedical, Inc.'s capital expenditures?

Lifecore Biomedical, Inc. (LFCR) invested $13.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Lifecore Biomedical, Inc. spend on research and development?

Lifecore Biomedical, Inc. (LFCR) invested $8.3M in research and development during fiscal year 2025.

How many shares does Lifecore Biomedical, Inc. have outstanding?

Lifecore Biomedical, Inc. (LFCR) had 37M shares outstanding as of fiscal year 2025.

What is Lifecore Biomedical, Inc.'s current ratio?

Lifecore Biomedical, Inc. (LFCR) had a current ratio of 2.84 as of fiscal year 2025, which is generally considered healthy.

What is Lifecore Biomedical, Inc.'s return on assets (ROA)?

Lifecore Biomedical, Inc. (LFCR) had a return on assets of -16.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Lifecore Biomedical, Inc.'s P/E ratio?

Lifecore Biomedical, Inc. (LFCR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $243.4M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Lifecore Biomedical, Inc.'s price-to-sales ratio?

Lifecore Biomedical, Inc. (LFCR) trades at 1.9x sales, its market capitalization divided by revenue of $128.9M revenue, FY2025. The market capitalization is $243.4M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is Lifecore Biomedical, Inc.'s debt-to-equity ratio negative or not reported?

Lifecore Biomedical, Inc. (LFCR) has negative shareholder equity of -$861K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Lifecore Biomedical, Inc.'s Altman Z-Score?

Lifecore Biomedical, Inc. (LFCR) has an Altman Z-Score of -0.01, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Lifecore Biomedical, Inc.'s Piotroski F-Score?

Lifecore Biomedical, Inc. (LFCR) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lifecore Biomedical, Inc.'s earnings high quality?

Lifecore Biomedical, Inc. (LFCR) reported a net loss of $38.7M while operations used $206K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Lifecore Biomedical, Inc. cover its interest payments?

Lifecore Biomedical, Inc. (LFCR) reported an operating loss of $17.2M against $22.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Lifecore Biomedical, Inc.?

Lifecore Biomedical, Inc. (LFCR) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.